Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › NJ › Raritan › NPI 1114690534
Lab

Cellvio Biomedical LLC

Cellvio Biomedical LLC was paid $502K by Medicaid between Mar 2022 and Jun 2022, across 4 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 70% of everything it billed.

33Billing provider infoCELLVIO BIOMEDICAL LLC
RARITAN, NJ 08869
33aNPI1114690534assigned 07/30/2021
28Total paid$502K
24GClaims19,092
24DCodes billed4
24AFirst – last monthMar 2022 – Jun 2022
Compared with peers

Next to other Clinical Medical Laboratory providers in New Jersey

Rank by total paid#73 of 122
Median peer was paid$1.29M
This provider vs. median0.4×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$100K$200K$300K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
202219,092$502K
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
U0004 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r 70% 6,459 4,090 $351K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 22% 6,097 3,902 $108K
G2023 Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source 8.5% 6,514 4,091 $43K
87426 Infectious agent antigen detection, SARS-CoV-2 (COVID-19) <1% 22 21 $903.89

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialPAYVANDI, FARIBOURZ (CEO)